Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
High blood pressure
Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments
Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...
Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at...
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
Chia Tai Tianqing’s Generic Entresto Approved by NMPA, Launch Expected in 2026
The National Medical Products Administration (NMPA) website has indicated that Chia Tai Tianqing’s generic version...
Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China
Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received...
Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...
Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth
Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second...
Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension
China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...
Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...
Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
PingAn Good Doctor Partners to Establish Lifestyle Medicine
China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...
Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform
Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an...
China Updates Hypertension Guidelines, Lowers Diagnostic Threshold
The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...